...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European respiratory review >Recent developments in the treatment of small cell lung cancer
【24h】

Recent developments in the treatment of small cell lung cancer

机译：近期细胞肺癌治疗的发展

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment remained relatively unchanged, with chemotherapy remaining the cornerstone of treatment. In this overview we will highlight the recent advances in the field of staging, surgery, radiotherapy and systemic treatment. Nevertheless, the prognosis remains dismal and there is a pressing need for new treatment options. We describe the progress that has been made in systemic treatment by repurposing existing drugs and the addition of targeted treatment. In recent years, immunotherapy entered the clinic with high expectations of its role in the treatment of SCLC. Unravelling of the genomic sequence revealed new possible targets that may act as biomarkers in future treatment of patients with SCLC. Hopefully, in the near future, we will be able to identify patients who may benefit from targeted therapy or immunotherapy to improve prognoses.
机译：小细胞肺癌（SCLC）包含约15％的肺癌。它是一种侵略性的疾病，早期转移和预后差。直到最近，SCLC治疗仍然保持相对不变，化疗留下了治疗的基石。在这一概述中，我们将突出近期分期，手术，放疗和全身治疗领域的进展。尽管如此，预后仍然令人沮丧，并且需要进行新的治疗选择。我们描述了通过重新施肥现有药物和添加有针对性的治疗来实现全身治疗的进展。近年来，免疫疗法进入了临床，对SCLC治疗中的作用很高。解开基因组序列揭示了新的可能靶标，可以作为生物标志物在未来治疗SCLC患者的患者中。希望在不久的将来，我们将能够识别可能受益于有针对性治疗或免疫疗法以改善预后的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号